Omeros Q3 net loss narrows; Novo Nordisk deal for zaltenibart up to $2.1B

OMEROS CORP

Q3 net loss $30.9M ($0.47/sh) vs $32.2M ($0.56/sh) a year ago; adjusted net loss $22.1M ($0.34/sh).
Entered up to $2.1B asset purchase/license deal with Novo Nordisk for zaltenibart; $240M upfront at Q4 2025 close.
Cash $36.1M at Sep 30; Q3 cash burn $22M ex-financing; raised $20.3M from Polar and $9M from ATM in Q3.
PDUFA date for narsoplimab in TA-TMA extended to Dec 26, 2025; commercial launch team ready with brand YARTEMLEA.
OMIDRIA royalties $9.2M in Q3 on net sales of $30.5M; operating expenses fell to $26.4M from $35.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.